Invion (ASX:IVXDB) - Stock Price, News & Analysis

IVXDB Stock Overview

A clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. More details

IVXDB fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Shares are highly illiquid

Earnings have declined by 14.1% per year over past 5 years

Does not have a meaningful market cap (A$14M)

+ 2 more risks

Invion Limited Competitors

Rhinomed

ASX:RNO

AU$11.5m

Emyria

ASX:EMD

AU$16.2m

Althea Group Holdings

ASX:AGH

AU$19.3m

Nyrada

ASX:NYR

AU$21.0m

Price History & Performance

Summary of all time highs, changes and price drops for Invion
Historical stock prices
Current Share Price	AU$0.21
52 Week High	AU$0.22
52 Week Low	AU$0.21
Beta	1.26
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	5.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	IVXDB	AU Pharmaceuticals	AU Market
7D	n/a	-16.4%	0.9%
1Y	n/a	32.3%	18.4%

Return vs Industry: Insufficient data to determine how IVXDB performed against the Australian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how IVXDB performed against the Australian Market.

Price Volatility

Is IVXDB's price volatile compared to industry and market?
IVXDB volatility
IVXDB Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	11.9%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.2%

Stable Share Price: IVXDB's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: Insufficient data to determine IVXDB's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	n/a	Thian Chew	www.inviongroup.com

Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, and solid cancers, such as lung, ovarian, anogenital, and glioblastoma multiforme cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion’s IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer.

Invion Limited Fundamentals Summary

How do Invion's earnings and revenue compare to its market cap?
IVXDB fundamental statistics
Market cap	AU$14.31m
Earnings (TTM)	-AU$5.63m
Revenue (TTM)	AU$3.69m

3.9x

P/S Ratio

-2.5x

P/E Ratio

Is IVXDB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IVXDB income statement (TTM)
Revenue	AU$3.69m
Cost of Revenue	AU$2.69m
Gross Profit	AU$1.00m
Other Expenses	AU$6.63m
Earnings	-AU$5.63m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.083
Gross Margin	27.16%
Net Profit Margin	-152.34%
Debt/Equity Ratio	0%

How did IVXDB perform over the long term?

See historical performance and comparison